Search This Blog

Monday, March 2, 2020

No, Bernie, ‘Medicare-for-all’ won’t save money

On Feb. 24, Sen. Bernie Sanders, I-Vt., released a document outlining how he plans to pay for his agenda, including “Medicare-for-all.” He claims his signature health plan will save the country billions of dollars each year.
That estimate rests on faulty math and flawed assumptions. Medicare-for-all would cost far more than Sanders admits and force Americans to pay dearly for subpar care.
The Democratic presidential frontrunner has gone to great lengths to avoid saying exactly how much the many new government programs he’s proposing would cost. “Nobody knows,” he said in an interview with CBS. But on Feb. 23, the senator let slip that his Medicare-for-all plan would cost around $30 trillion over a decade.

Most economists peg the cost a bit higher. The Mercatus Center forecasts around $32 trillion over 10 years; the left-leaning Urban Institute, about $34 trillion.
But neither estimate includes the cost of a new federal long-term care entitlement, which Sanders has tacked onto his Medicare-for-all plan since the two think tanks did their analysis. Add that in, and the 10-year cost of Medicare-for-all swells to a $46 trillion, per a recent American Action Forum analysis.

Sanders imagines funding Medicare-for-all with taxes that would strain the economy and American families. He’s floated a new 4 percent income tax on all households earning over $29,000 a year, a new 7.5 percent payroll tax, and a new corporate income tax rate of 35 percent. That would make U.S. corporate income taxes the highest in the world and result in lower wages for workers. He’s also proposed higher taxes on the wealthy and on capital gains.

Those high taxes would make Medicare-for-all a bad deal for many Americans. Emory University professor Kenneth E. Thorpe estimates that 70 percent of working, privately insured households would pay more for health insurance under Medicare-for-all than they currently do.
All these new taxes would not come close to covering the cost of Medicare-for-all. Together, they’d generate about $17.5 trillion — just over half of what Sanders estimates Medicare-for-all would cost and about one-third of the American Action Forum’s more realistic estimate.
Sanders has taken to touting the supposed savings Medicare-for-all would deliver in order to distract from concerns about its cost. His latest piece of “evidence” is a study published by a Yale epidemiologist and unpaid advisor to his campaign in the medical journal The Lancet claiming that Medicare-for-all would save the United States $450 billion every year and save 68,000 lives.
There are several problems with this study. For starters, $100 billion of these savings would come from reimbursing doctors and hospitals at Medicare’s existing rates, which are much lower than those currently paid by private insurers. The study acknowledges as much but argues that healthcare providers would happily accept pay cuts in exchange for reduced administrative costs.
Healthcare providers have successfully staved off just about every pay cut Congress has threatened over the past two decades. Further, Democrats in Congress have stopped well short of foisting Medicare-style price controls on surprise medical bills, as Avik Roy of the Foundation for Research on Equal Opportunity has pointed out. If they can’t muster the political courage to cap something as universally reviled as surprise medical bills, they’re unlikely to do so across the entire healthcare system.
Second, the study assumes $219 billion in administrative savings, if Medicare-for-all matches the current Medicare program’s level of overhead. But many of the administrative costs currently borne by the private sector wouldn’t disappear under Medicare-for-all. They’d shift to other parts of the federal government.
The IRS would have to spend more money collecting taxes. The Department of Health and Human Services would have to build a huge new infrastructure to process claims and investigate fraud. On that front, the government’s track record isn’t great, given that about 10 percent of Medicare’s existing payments are fraudulent.

Perhaps most important, the Yale study Sanders cites assumes that millions of people who already have health insurance will not consume any more care after Medicare-for-all makes it “free.” That runs counter to the basics of supply and demand. Make care cheaper, and people will demand more of it. If taxpayer-funded care induces additional demand, much of Sanders’ savings will vanish.
Sanders’ plan to pay for Medicare-for-all amounts to little more than wishing for savings that will never materialize.
https://www.foxnews.com/opinion/sally-pipes-medicare-all-save-money

Big Fed rate cuts baked into futures prices as virus spreads

The U.S. central bank will deliver a big dose of stimulus starting this month in a bid to protect the world’s biggest economy from the impact of the coronavirus, traders of futures contracts tied to Federal Reserve policy are betting.
Traders see a 100% chance of a half percentage-point rate cut at the Fed’s March meeting, according to CME Group’s FedWatch, which translates fed funds futures pricing into traders’ monetary policy expectations. Another half a percentage point-cut is priced in by July.
That is up from no chance of large cuts seen last week, and reflects rising global expectations that global central banks will take coordinated action to fend off the worst effects of a world economic slowdown as factories and schools close and public events are canceled in efforts to slow the virus’ spread.
The Fed delivered three quarter-point rate cuts last year, and policymakers had projected that with continued economic growth and low unemployment, there would be no need for further adjustments.
But that was before the virus spread in China and dozens of countries, including the United States.

World stock markets fell sharply last week, as a result. New U.S. cases, along with deaths connected to an outbreak near Seattle, look likely to present a “material change” to the outlook that Fed Chair Jerome Powell said could trigger action.
On Friday Powell said the central bank would “act as appropriate” to support the economy, and early Monday Bank of Japan Governor Haruhiko Kuroda said he would “strive to stabilize” markets roiled by virus fears.
U.S. President Donald Trump on Monday renewed his call for the Fed to lower interest rates, tweeting that the central bank has been “slow to act.”
Finance ministers of seven big economies, and their central bankers, will meet by conference call on Tuesday to discuss possible coordinated action, Bloomberg News reported.

There are doubts about how effective such action could be. That is partly because of the nature of the threat: Central bank and fiscal policy can boost demand by lowering the cost of borrowing and putting money in people’s wallets. But they cannot repair disrupted global supply chains or convince people to fly, attend meetings or even go to school, especially if local governments or companies bar such activities.
The challenge for monetary policy also comes from the fact that interest rates globally are already at low levels. The European Central Bank and the Bank of Japan, which have pushed interest rates below zero, may be particularly challenged to find ways to cushion their economies from the effects of the coronavirus.
https://www.reuters.com/article/us-usa-fed-futures/big-fed-rate-cuts-baked-into-futures-prices-as-virus-spreads-idUSKBN20P2CD

Trump: asked drugmakers to speed virus vax as he plans to meet execs

President Donald Trump said Monday he’s asked pharmaceutical companies to speed up work on a coronavirus vaccine, ahead of an afternoon meeting with drug-company executives.
“We’ve asked them to accelerate” work, Trump told reporters during a meeting with Colombian President Ivan Duque at the White House.
The president, joined by Vice President Mike Pence and members of the administration’s coronavirus task force, is scheduled to meet with the executives at the White House at 3 p.m. Eastern. The executives’ names and companies haven’t yet been released by the administration.
The U.S., which has reported multiple instances of transmission of the illness, now has a total of 86 cases and two deaths from COVID-19, a novel coronavirus that was first detected in China in December.
https://www.marketwatch.com/story/trump-to-meet-with-pharmaceutical-executives-as-second-coronavirus-death-in-us-reported-2020-03-02

Sen. Chris Murphy admits to meeting with Iranian foreign minister

Feb. 19, 2020 – 6:29 – Trump questions whether meeting violates Logan Act; Fox News contributors Richard Fowler and Mollie Hemingway react.
https://video.foxnews.com/v/embed.js?id=6133680984001&w=466&h=263
https://video.foxnews.com/v/6133680984001#sp=show-clips

Insulet down 5% on Omnipod Horizon software glitch

Insulet (PODD -4.8%) is down on average volume on the heels of its announcement that it will pause the pivotal study of its Omnipod Horizon Automated Glucose Control System in order to correct a software “anomaly” that could result in the system using an incorrect glucose value that could impact insulin delivery. No adverse events related to the issue have been reported.
Updated software should be available by the end of April.
The company says the problem will “modestly impact” market launch, now expected in early 2021 (from H2 2020).
https://seekingalpha.com/news/3547461-insulet-down-5-on-omnipod-horizon-software-glitch

European advisory group backs Takeda’s brigatinib for type of lung cancer

The European Medicines Agency’s advisory group CHMP has adopted a positive opinion recommending approval of Takeda’s (TAK +0.4%) Alunbrig (brigatinib) as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) who have not received prior treatment with an ALK inhibitor.
A final decision from the European Commission usually takes ~60 days.
https://seekingalpha.com/news/3547494-european-advisory-group-backs-takedas-brigatinib-for-type-of-lung-cancer

Mallinckrodt launches rolling application for terlipressin for HRS-1

Mallinckrodt (MNK -4.8%) has initiated the rolling submission of its U.S. marketing application for terlipressin for the treatment of hepatorenal syndrome type 1 (HRS-1), a type of progressive kidney failure in patients with severe liver damage.
The clinical data package was the first to be filed. It expects to complete the submission in the coming months.
Investors appear to be reacting to the timeline. In August 2019, it announced that it expected to file the application in Q1.
https://seekingalpha.com/news/3547504-mallinckrodt-launches-rolling-application-for-terlipressin-for-hrsminus-1